Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Artificial Intelligence in Clinical Chemistry: Dawn of a New Era?

Indian journal of clinical biochemistry : IJCB·2023
Same author

Amplification of the <i>BCR::ABL1</i> Fusion Gene: A Rare Phenomenon in B-cell Acute Lymphoblastic Leukemia.

Turkish journal of haematology : official journal of Turkish Society of Haematology·2023
Same author

Over 30 Years of Omeprazole.

The Journal of the Association of Physicians of India·2023
Same author

Public Knowledge, Awareness, and Vaccination Rates for Hepatitis B in India: A Cross-Sectional Survey.

Cureus·2023
Same author

Sustainable approach for adsorptive removal of cationic and anionic dyes by titanium oxide nanoparticles synthesized biogenically using algal extract of<i>Spirulina</i>.

Nanotechnology·2023
Same author

An intriguing case of childhood primary bone marrow histiocytic sarcoma: A diagnostic challenge.

International journal of laboratory hematology·2023

Related Experiment Video

Updated: Jun 14, 2026

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

Minimal hepatic encephalopathy.

Praveen Sharma1

  • 1Department of Hepatology, Institute of Liver and Biliary Sciences, Delhi.

The Journal of the Association of Physicians of India
|March 25, 2010
PubMed
Summary

Minimal hepatic encephalopathy (MHE) affects up to 80% of cirrhosis patients, causing cognitive deficits impacting daily life. Diagnosis often requires multiple tests, with lactulose remaining the primary treatment.

Area of Science:

  • Hepatology
  • Neuropsychology
  • Clinical Medicine

Background:

  • Minimal hepatic encephalopathy (MHE) presents cognitive and neurophysiological deficits in cirrhosis patients with normal clinical exams.
  • MHE prevalence can reach 80% in cirrhotic populations.
  • This condition impairs daily functioning and quality of life, independent of intelligence or sleep issues.

Purpose of the Study:

  • To highlight the diagnostic challenges and current treatment landscape of Minimal Hepatic Encephalopathy.
  • To emphasize the significance of MHE as a predictor of overt hepatic encephalopathy.

Main Methods:

  • Review of existing literature on MHE diagnosis and treatment.
  • Evaluation of diagnostic tools, noting the absence of a "gold standard".

More Related Videos

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury

Published on: October 21, 2017

Related Experiment Videos

Last Updated: Jun 14, 2026

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy
10:30

A Piglet Model of Neonatal Hypoxic-Ischemic Encephalopathy

Published on: May 16, 2015

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury
07:27

The Murine Choline-Deficient, Ethionine-Supplemented (CDE) Diet Model of Chronic Liver Injury

Published on: October 21, 2017

  • Assessment of current therapeutic mainstays and emerging treatments.

    • Main Results:

    • MHE is characterized by psychomotor slowing, attention deficits, and impaired fine motor skills.
    • A combination of diagnostic methods is recommended due to the lack of a definitive "gold standard".
    • Lactulose is the current primary treatment, with probiotics and ornithine aspartate under investigation.

    Conclusions:

    • MHE is a significant complication of cirrhosis with substantial impact on patient well-being.
    • Accurate diagnosis of MHE is crucial for timely intervention and management.
    • Further research into alternative therapies beyond lactulose is warranted.